Make a Difference with a Donation

Covid 19 & EGID’s


Fast Facts about COVID -19 & EGIDs from Dr. Marc Rothenburg

  • We do not have substantial data about COVID-19 and EGID.
  • We do know that EGID is not an immune-deficiency disease.
  • There is no known risk for viral infections in EGID patients.
  • Patients on eosinophil depleting drugs such as benralizumab and patients with eosinophilia have not been reported to have an increased risk of viral infections and/or complications from viral infections, indicating that eosinophil dysregulation (increased or decreased levels) is not a primary response against viruses.
    Fluticasone and Budesonide are not systemic steroid medications, and therefore there’s no immune suppression.


Patients in research studies should make personal decisions about the risk/reward of continuing to participate.

Contact your specific research trial team for specific questions regarding your trial. 

A caveat to this information concerns rare EGID patients that may have another underlying disease or EGID patients on systemic steroids; these patients may have some increased risk for complications.   Such patients should consult with their primary doctor for specific advice and guidance.
Patients with concerns should contact their health provider on a case by case basis. This is still a very fluid situation.
Also check and

In view of the evolving COVID-19 infection, we advise patients and their families to follow the CDC’s recommendations for travel, preventative measures and preparedness at Stay updated with your state and local health department’s advisories for your area.

provided by CURED Medical Advisory Board Member

Marc E. Rothenberg MD, PhD

Professor of Pediatrics

Bunning Chair of Allergy and Immunology

Director, Division of Allergy and Immunology

Director, Cincinnati Center for Eosinophilic Disorders

Cincinnati Children’s Hospital Medical Center

SSL Certificate security seal